VERSENATE SUMMARY
Calcium Disodium Versenate (edetate calcium disodium injection, USP) is a sterile, injectable, chelating agent in concentrated solution for intravenous infusion or intramuscular injection. Each 2.5 ml ampul contains 500 mg of edetate calcium disodium (equivalent to 200 mg/ml) in water for injection.
Edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.
Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead.
|
NEWS HIGHLIGHTS
Published Studies Related to Versenate (Edetate Calcium Disodium)
Random serial sampling to evaluate efficacy of iron fortification: a randomized controlled trial of margarine fortification with ferric pyrophosphate or sodium iron edetate. [2010.11] BACKGROUND: Random serial sampling is widely used in population pharmacokinetic studies and may have advantages compared with conventional fixed time-point evaluation of iron fortification. OBJECTIVE: Our objective was to validate random serial sampling to judge the efficacy of iron fortification of a low-fat margarine... CONCLUSIONS: When used to evaluate the efficacy of iron fortificants, random serial sampling can reduce the sample size, invasiveness, and costs while increasing sensitivity. Random serial sampling more clearly describes the pattern of iron repletion and may prove useful in evaluating other micronutrient interventions.
A randomised double-blind study comparing sodium feredetate with ferrous fumarate in anaemia in pregnancy. [2007.05] Iron deficiency anaemia is a major health problem in India especially in women of reproductive age group. The World Health Organisation recommends that the haemoglobin concentration should not fall below 11.0 g/dl at any time during pregnancy... As there were no adverse effects reported with sodium feredetate, it can be concluded from this study that this new formulation appears to be effective in improving haemoglobin profile in pregnant anaemic women and is tolerated well.
Clinical Trials Related to Versenate (Edetate Calcium Disodium)
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR) [Recruiting]
The purpose of this study is to validate in comparison to a reference method (inuline) two
novel non-radioactive biomarkers for glomerular filtration rate (GFR) measurement in
chronic-kidney disease (CKD) patients and in healthy volunteers: Calcium-EDTA and Gd-DOTA.
Prolonged Gadolinium Retention After MRI Imaging [Not yet recruiting]
The researchers propose to investigate the prevalence of gadolinium in the urine of patients
with a prior gadolinium-enhanced MRI before and after a edetate calcium disodium challenge.
Moreover, will investigate if there is any correlation of gadolinium urine levels with
levels of endogenous (e. g zinc) and xenobiotic metals.
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies [Withdrawn]
RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium
disodium, and ethanol may help prevent blockages and infections from forming in patients
with central venous access catheters or peripheral venous catheters.
PURPOSE: This randomized trial is studying an antimicrobial solution or saline solution in
maintaining catheter patency and preventing catheter-related blood infections in patients
with malignancies.
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia [Completed]
This study will examine the use of a radioactive monoclonal antibody called yttrium
90-labeled humanized anti-Tac (90 Y-HAT) for treating certain cancers. Monoclonal antibodies
are genetically engineered proteins made in large quantities and directed against a specific
target in the body. The anti-Tac antibody in this study is targeted to tumor cells and is
tagged (labeled) with a radioactive substance called Yttrium-90 (Y-90). The study will
determine the maximum tolerated dose of 90Y-HAT and examine its safety and effectiveness.
Patients 18 years of age and older with Hodgkin's disease, non-Hodgkin's lymphoma and
lymphoid leukemia who have proteins on their cancer cells that react with anti-Tac may be
eligible for this study. Candidates are screened with a medical history and physical
examination, blood and urine tests, electrocardiogram (EKG), chest x-ray, CT scan or
ultrasound of the abdomen, PET scan of the neck and body, and skin test for immune
reactivity to antigens (similar to skin tuberculin test).
Before beginning treatment, participants may undergo additional procedures, including the
following:
- Patients with suspicious skin lesions have a skin biopsy. An area of skin is numbed and
a circular piece of skin about 1/4-inch diameter is removed with a cookie cutter-like
instrument.
- Patients with hearing loss have a hearing test.
- Patients with neurological symptoms have a lumbar puncture (spinal tap). A local
anesthetic is given and a needle is inserted in the space between the bones in the
lower back where the cerebrospinal fluid circulates below the spinal cord. A small
amount of fluid is collected through the needle.
- Patients who have not had a bone marrow biopsy within 6 months of screening also
undergo this procedure. The skin and bone at the back of the hip are numbed with a
local anesthetic and a small piece of bone is withdrawn through a needle.
Patients receive 90 Y-HAT in escalating doses to determine the highest dose that can be
safely given. The first group of three patients receives a low dose and, if there are no
significant side effects at that dose, the next three patients receive a higher dose. This
continues with subsequent groups until the maximum study dose is reached. 90 Y-HAT is given
through a vein (IV) over a 2-hour period. In addition, a drug called Ca-DTPA is given via IV
over 5 hours for 3 days to help reduce the side effects of the 90Y-HAT. In some patients,
the 90 Y-HAT may also be attached to a radioactive metal called Indium-111 to monitor what
happens to the injected material. During infusion of the drug, patients undergo PET scanning
to trace the path of the injected material in the body. For this procedure, the patient lies
in the scanner, remaining in one position during the entire infusion.
Blood and urine specimens are collected periodically over a 6-week period following the
infusion to determine the level of the radioactive antibody. Bone marrow, lymph node, or
skin biopsies may be done to determine how much of the antibody entered these sites.
Patients whose disease remains stable or improves with therapy may receive up to six more
infusions of 90 Y-HAT , with at least a 6-week interval between treatments.
Monoclonal Antibody Therapy in Treating Patients With Leukemia [Completed]
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody
plus pentetic acid calcium in patients with leukemia.
|